Evaluation of an automated algorithm for interpretation of lupus anticoagulant testing by Florin, Lisa et al.
Int J Lab Hematol. 2019;1–6.	 wileyonlinelibrary.com/journal/ijlh	 	 | 	1© 2019 John Wiley & Sons Ltd
1  | INTRODUC TION
The antiphospholipid syndrome (APS) is defined in a patient if at 
least one clinical and one laboratory criterion are fulfilled. The clin‐
ical criterion is characterized by the manifestation of recurrent vas‐
cular thrombosis and/or pregnancy morbidity. For the presence of 
the laboratory criterion, antiphospholipid antibodies (APA) must be 
demonstrable in patient's plasma on two or more occasions at least 
12 weeks apart. As the incidence of the clinical symptoms is high 
and symptoms may be attributable to many other underlying fac‐
tors, diagnosis of the APS relies mainly on the laboratory criterion. 
The laboratory detection of aPL consists of phospholipid‐dependent 
coagulation tests for the detection of lupus anticoagulant (LAC) and 
immunoassays for the measurement of anti‐cardiolipin antibodies 
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Abstract
Introduction: Lupus anticoagulant (LAC) testing is a multistep procedure including 
screening, mixing, and confirmation tests. STA Coag Expert is a software module for 
STA R Max and STA Compact Max analyzers which includes an on‐demand LAC algo‐
rithm, based on ISTH guidelines, for automatic interpretation, calculation, and launch 
of assays in LAC interpretation (“Stago coag algorithm”).
Materials and methods: One hundred ninety four patient samples were analyzed in 
parallel and interpreted manually and automatically by LAC algorithms. LAC algo‐
rithms use identical flowcharts and cutoff values as in daily practice. Differently, it 
only uses index of circulating anticoagulant (ICA), whereas in routine also normalized 
ratios were assessed for interpretation of mixing tests. Interpretation of dRVVT and 
aPTT pathways and final conclusions were compared between both approaches.
Results: Compared to routine interpretation, LAC algorithm showed a sensitivity of 
94% and a specificity of 100% for LAC detection, when discrepancies due to meas‐
ured clotting times between both analyzers were excluded. Three false negatives 
were due to different interpretation of dRVVT mixing test. Discrepancies in interpre‐
tation of the aPTT mixing test (n = 11) did not result in discrepant final LAC result, all 
having negative confirmation tests. No false positives were observed. With LAC al‐
gorithm, hands‐on time reduced from 200 to 80 minutes.
Conclusion: The LAC algorithm of the STA Coag Expert shows good comparability to 
the manual interpretation of LAC and may be used to assist laboratories in automatic 
launching of additional tests and in interpretation of LAC according to ISTH guide‐
lines. This way the STA Coag Expert LAC algorithm may improve interlaboratory and 
STA comparability of LAC results.
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and anti‐beta‐2 glycoprotein I antibodies.1 Detection of LAC in the 
laboratory is subject to some difficulties in standardization: The 
spectrum of aPL is heterogeneous and variable, the assay consists 
of a multistep testing procedure with a screening, mixing, and con‐
firmation step, and many different assay principles and reagents are 
available, possible interference of anticoagulant medication and lack 
of a gold standard.2,3 In 2009, the Scientific and Standardization 
Committee (SSC) of the International Society on Thrombosis and 
Haemostasis (ISTH) published recommendations for LAC detection, 
specifying who, when, and how to test for LAC, thereby aiming to 
improve the harmonization of the assay.4
Despite these recommendations, performance and interpreta‐
tion of LAC tests remain a challenge.3,5 Besides inadequate stan‐
dardization of assays, differences in local working conditions and 
difficulties in correct interpretation of the results may lead to false 
results. Interpretation of the different steps in the LAC test pro‐
cedure is based on exceeding the local cutoff values expressed as 
normalized ratio to normal pool plasma. Except for the mixing step, 
the ISTH guideline also allows the interpretation through the Rosner 
index (index of circulating anticoagulant) as an alternative for the 
measured clotting time.4 The presence of anticoagulant medication 
impedes correct interpretation, since vitamin K antagonists may give 
false‐negative results in the mixing step and direct oral anticoagu‐
lant therapy may cause false‐positive results.6 Standardized inter‐
pretation according to the in‐house established cutoff values of all 
three steps benefits harmonization and reproducibility of the final 
LAC results. Also, generating comments on the result, especially in 
anticoagulated patients, and a global final conclusion help the clini‐
cian in the interpretation of the result.4
An automated algorithm with launch of the mixing step and confir‐
mation step based on predefined cutoff values and calculations with‐
out need for intervention from the laboratory technician may benefit 
a uniform method of LAC detection and a standardized interpretation 
reducing the intralaboratory and interlaboratory variation. STA Coag 
Expert is a software module for Stago STA R Max & STA Compact 
Max analyzers including an on‐demand LAC algorithm. We evaluated 
this algorithm and compared it with the manual LAC interpretation.
2  | MATERIAL S AND METHODS
2.1 | Patient samples
One hundred ninety four samples with LAC request, due to a di‐
agnostic work‐up of hypercoagulability, pregnancy complications, 
autoimmune disease, or a prolonged activated partial thromboplas‐
tin time (aPTT), were analyzed at the Ghent University Hospital. 
Patients treated with anti‐vitamin K therapy (VKA), direct oral an‐
ticoagulant therapy (DOAC), unfractionated heparin (UFH), or low 
molecular weight heparin (LMWH) were included. Samples were 
drawn and prepared according to the guidelines.4 Samples were 
stored	at	−20°C	for	a	maximum	of	one	week	until	analysis	in	batch.	
This study was approved by the ethical committee of the Ghent 
University Hospital.
2.2 | Lupus anticoagulant testing
Lupus anticoagulant testing was performed in our routine prac‐
tice according to the ISTH guidelines on STA‐R Evolution (Stago, 
Asnières, France) and in parallel with the automated LAC algorithm, 
only available on STA R Max (Stago).4
In routine practice, LAC screening tests were carried out in two 
systems with an aPTT (PTT‐LA®, Stago) and a dilute Russell's viper 
venom time (dRVVT) (STA‐Staclot® dRVV Screen, Stago). For mix‐
ing tests, patient plasma was diluted 1:1 with pooled normal plasma 
(NPP), prepared in‐house by mixing citrated plasma from 75 healthy 
volunteers. Confirmation tests were performed in aPTT with hexag‐
onal phase phospholipids (Staclot® LA, Stago) and in dRVVT with 
a phospholipid‐rich dRVVT reagent (STA‐Staclot® DRVV confirm, 
Stago).4 The Staclot® LA aPTT confirmation test was performed 
only on STA‐R Evolution and was not repeated on STA R Max, since 
this is a partly manual assay (incubation of patient's plasma with and 
without hexagonal phase phosphatidylethanolamine occurs outside 
the analyzer, samples are only placed onboard after incubation for 
measurement of aPTT). For each batch analysis of 30 patient sam‐
ples, a NPP sample was analyzed to be used for normalization of the 
clotting times to achieve clotting time ratio's for screening, mixing, 
and confirm assays.4 Local cutoffs for screen, mixing, and confirm 
tests were calculated by the 99th percentile on 120 healthy donors 
and were similarly applied in the software program and with the 
manual interpretation. A quality control sample preceded every run 
of patient samples. In routine practice, mixing tests were performed 
if calculated normalized clotting time ratio's (NCR) for aPTT and/
or dRVVT exceeded the normalized cutoff ratios. The confirmation 
step for prolonged dRVVT was performed independent of the re‐
sult of the mixing test. A confirmation test for prolonged aPTT was 
performed if the NCR or index of circulating anticoagulant (ICA) of 
the mixing test for aPTT exceeded the cutoffs. LAC was considered 
positive if (a) the screening step was prolonged, (b) the mixing test 
ratio (either NCR and/or ICA) was prolonged, and (c) the confirma‐
tion step was exceeded the normalized reference ratio.4 With the 
LAC algorithm on STA R Max, the same procedures were applied, 
except that the algorithm only uses ICA for interpretation of the 
mixing step and not the normalized ratio. LAC algorithm on STA R 
Max was compared to routine analysis of LAC on STA‐R Evolution 
in terms of interpretation, reagent consumption, and hands‐on time 
on the analyzer.
2.3 | STA Coag Expert
STA Coag Expert is a software module for Stago STA R Max and 
STA Compact Max analyzers (Stago, Asnières, France) that includes 
a LAC algorithm, specific mathematical rules for automatic launching 
of screening, mixing, and confirm assays without need for interven‐
tion from the laboratory technician. Local cutoffs are user‐defined 
parameters within the software, that are configured when the soft‐
ware is installed. Test results are calculated and interpreted by the 
algorithm and recommendations for actions for the different results 
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are proposed. LAC algorithm was developed by Stago in collabora‐
tion with an expert group, following ISTH guidelines.4
Applying other guidelines (for instance from the Clinical and 
Laboratory Standards Institute (CLSI)7) would have affected the 
structure of the algorithm since guidelines differ at some points. The 
main issues that would have been different are as follows: order of 
screening, mixing, confirmation step, the choice of assays, and nor‐
malization of results.7
According to the ISTH guidelines, the order of the multistep 
procedure is screening, mixing, confirmation, also for paired tests, 
to avoid false‐positive results.3,8,9 The CLSI guideline advises for 
paired tests (dRVVT) to perform the mixing step if the confirmation 
step is negative, so the order of screening, mixing, and confirma‐
tion step differs between both guidelines.7 To reduce the number 
of false positives and to obtain more harmonization in LAC testing, 
the ISTH guidelines recommend aPTT and dRVVT tests, and do not 
recommend other assays to be included. CLSI guidelines prefer also 
aPTT and dRVVT, but do not exclude other assays. In the evaluated 
algorithm, only aPTT and dRVVT are included. The interpretation of 
results is determined by the cutoff values and plays a major role in 
classifying a sample as LAC positive or negative. The software allows 
to use the local cutoff values. Although calculation of cutoffs dif‐
fers between the guidelines, this will not hamper using the algorithm 
since the user can configure the software with own cutoff values. In 
the ISTH guidelines, normalization of results is performed by apply‐
ing the value of a normal pooled plasma performed in each run. CSLI 
allows the use of a reference mean for each batch of reagent. Using 
a fixed value to normalize results is not possible in the algorithm the 
way it is now configured.
The algorithm is illustrated in Figure 1.
3  | RESULTS
3.1 | Lupus anticoagulant interpretation of dRVVT 
system
Tables 1 and 2 show the results of dRVVT pathway, aPTT pathway, 
and final LAC interpretation on both Stago instruments. Out of 194 
samples, 37 were positive in dRVVT system (positive screening, mix‐
ing, and confirmation test) for both routine interpretation and with 
LAC algorithm and 143 were negative with both systems, yielding a 
sensitivity of 76% and a specificity of 99% for LAC algorithm on STA 
R Max, as compared to the results obtained without the algorithm on 
STA‐R Evolution. Two false‐positive results were observed on STA R 
Max, due to differences in measured seconds in screening test be‐
tween both analyzers, and not due to differences in LAC interpreta‐
tion (routine interpretation vs LAC algorithm). Twelve false‐negative 
results were observed on STA R Max: nine false negatives were due 
F I G U R E  1   Flowchart of the lupus anticoagulant algorithm as applied by the STA Coag Expert software of Stago. “…” depict comments 
proposed by the software. APA, antiphospholipid antibodies (anti‐cardiolipin and anti‐β2 glycoprotein I antibodies) [Colour figure can be 
viewed at wileyonlinelibrary.com]
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to discrepancies in measured clotting times and three false‐negative 
results were caused by differences in interpretation of dRVVT mix‐
ing test. For these three samples, the NCR was positive and the ICA 
was negative in routine practice,10,11 which resulted together with 
a positive screening and confirmation test in a positive LAC result, 
whereas ICA was negative on STA R Max, causing a negative LAC 
interpretation. In conclusion, of 194 analyzed samples, 14 discrep‐
ancies were observed in dRVVT test between both platforms, but 
only 3/14 discrepancies were due to different interpretation of LAC.
3.2 | Lupus anticoagulant interpretation of 
aPTT system
In the aPTT system, 16 samples were positive on both platforms 
and 173 samples were mutually negative, yielding a sensitivity and 
specificity of the LAC algorithm on STA R Max of, respectively, 84% 
and 99%. Five discrepant results were observed: two false positives 
and three false negatives, all due to differences in measured clotting 
times. Four out of five discrepancies did not result in a discrepancy 
in final LAC interpretation since dRVVT system was positive on both 
platforms for those samples. Twenty discrepancies occurred in aPTT 
mixing test, nine due to differences in clotting times and 11 due to a 
positive NCR but a negative ICA.10,11 However, the 20 false‐negative 
aPTT mixing tests with LAC algorithm on STA R Max did not result in 
a difference in LAC interpretation since the aPTT confirmation tests 
were negative.
3.3 | Final LAC conclusion
For final LAC conclusion, there were no false‐positive results of LAC 
algorithm on STA R Max compared to routine interpretation on STA 
R Evolution, since the false positives in the dRVTT system (n = 2) 
were positive on both platforms in the aPTT system, and vice versa 
the false positives in the aPTT system (n = 2) were positive on both 
platforms in the dRVVT system, resulting in a specificity of 100% 
compared to routine interpretation.
Eleven false‐negative results were observed (10 in dRVVT sys‐
tem and one in aPTT system), yielding a sensitivity of 80%. Three 
out of 11 discrepancies were due to the different interpretation of 
dRVVT mixing test, the other eight discrepancies were caused by 
differences in measured seconds on both platforms. Excluding these 
eight samples, sensitivity of LAC algorithm for detection of lupus 
anticoagulant increased to 94%, and specificity remained at 100%.
3.4 | Comments on results
The STA Coag Expert software appended comments to the results of 
aPTT and dRVVT screen, mixing, and confirmation steps (Figure 1). 
When aPTT screen, mix, and/or confirm were negative, a comment 
was generated to check for clinically relevant intrinsic factor defi‐
ciencies of factor VIII, IX, or XI, which may also prolong the aPTT 
and can cause bleeding tendency. Alternatively, when aPTT and/or 
dRVVT screen were positive, an automated comment warned that 
unfractionated heparin (UFH), LMWH, VKA, or DOAC may cause 
interference with LAC testing. A prolonged dRVVT confirm ratio 
may be provoked by VKA or DOAC therapy, and thus, the comment 
TA B L E  1   2 x 2 contingency table for screen, mixing step, 
confirmation, and conclusion of dRVVT pathway (A) and aPTT 
pathway (B)
LAC algorithm on 
STA R Max
Routine LAC interpretation on STA‐R 
evolution
 Positive Negative Total
(A) dRVVT
Screen Positive 65 3 68
Negative 2 124 126
Total 67 127 194
Mix Positive 49 0 49
Negative 10 8 18
Total 59 8 67
Confirm Positive 51 1 52
Negative 3 12 15
Total 54 13 67
Conclusion Positive 37 2 39
Negative 12 143 155
Total 49 145 194
(B) aPTT
Screen Positive 60 1 61
Negative 5 128 133
Total 65 129 194
Mix Positive 31 0 31
Negative 20 14 34
Total 51 14 65
Confirm Positive 20 0 20
Negative 0 31 31
Total 20 31 51
Conclusion Positive 16 2 18
Negative 3 173 176
Total 19 175 194
LAC algorithm on STA R Max was compared to routine LAC interpreta‐
tion on STA‐R Evolution
TA B L E  2   Number of positive and negative results for final 
conclusion of lupus anticoagulant applied by LAC algorithm on STA 
R Max, compared to routine LAC interpretation on STA‐R Evolution
LAC algorithm on STA 
R Max
Routine LAC interpretation on STA‐R 
Evolution
Positive Negative Total
LAC conclusion
Positive 43 0 43
Negative 11 140 151
Total 54 140 194
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“check VKA or DOAC therapy” was added by the software in this 
situation. Different comments were possible for the interpretation 
of the dRVVT pathway, depending on the combination of the re‐
sults of the mixing and confirmation step. A negative mixing step 
but a positive confirmation step may be due to VKA therapy, so the 
software proposed to check international normalized ratio (INR).8,9 
Conversely, when mixing step was positive but confirmation step 
was negative, the STA Coag Expert software advised to check DOAC 
therapy. Meanwhile, experience with DOAC has learned, depending 
on the type of DOAC, the level of DOAC, and the reagent used, that 
DOAC can influence all clotting tests in LAC measurement, mainly 
affecting the dRVVT test system. A warning for DOAC at each level 
of a positive dRVVT test should be more appropriate.12 A final con‐
clusion was given for every sample, depending on results of aPTT 
and dRVVT pathway. If positive, it was advised by the software to 
confirm LAC in 12 weeks and to interpret results together with the 
other APA (anti‐cardiolipin antibodies and anti‐beta‐2 glycoprotein 
I antibodies).
3.5 | Reagent consumption and hands‐on time
All LAC tests, except the aPTT confirmation test (Staclot® LA), were 
run automatically on the STA R Max analyzer, and consequently, all 
reagents needed to be placed in sufficient quantity onboard pre‐
launching the LAC assays. Therefore, both methods did not differ in 
reagent consumption, except for the Staclot® LA aPTT confirmation 
test. With LAC algorithm on STA R Max, 10% (20/194) less Staclot® 
LA tests needed to be performed without differences in LAC inter‐
pretation (20 aPTT mixing tests negative with LAC algorithm and 
positive with the routine method, but all with negative Staclot® re‐
sults). For every run of 30 samples, in our working conditions, hands‐
on time for the technician on STA R Max decreased by 60% from 
200 to 80 minutes since the laboratory technician did not need to 
supervise and interpret the multistep test procedure once samples 
were placed onboard.
4  | DISCUSSION
Lupus anticoagulant analysis is complex, including the three steps 
that are necessary to evaluate the presence of LAC.4 Many pitfalls 
in interpretation of LAC may influence the results: The LAC antibod‐
ies are heterogeneous, reagents are not standardized, and there is 
no gold standard.3 The multistep methodology might be a source of 
interlaboratory variation based on different interpretation of results. 
An automated algorithm may contribute to more harmonized perfor‐
mance of the multistep procedure and to more standardized inter‐
pretation. In‐house developed algorithm or commercially available 
software modules can contribute to this goal. To facilitate LAC analy‐
sis and to increase between‐laboratory standardization of LAC inter‐
pretation, an automated algorithm launching tests based on defined 
cutoff values and calculating results was developed by Stago based 
on expert's recommendations. This algorithm is executed through 
the STA Coag Expert software module. In this study, 194 patient 
samples were run on STA‐R Evolution with routine interpretation of 
LAC assays and compared to the automated LAC interpretation with 
LAC algorithm on STA R Max. LAC algorithm uses the same flow‐
chart and cutoff values for screen, mixing, and confirm assays for 
dRVVT and aPTT pathways as applied in routine practice. Both rou‐
tine interpretation of results and LAC algorithm follow the ISTH‐SSC 
recommendations.4 In the current version of the LAC algorithm, only 
ICA was implemented for interpretation of mixing tests, whereas in 
daily practice also NCR was assessed. Although guidelines are not 
yet adapted on the interpretation of mixing tests, recent studies have 
shown that the NCR is more sensitive compared to ICA.10,11
Differences in LAC results between both methods were mainly 
due to minor differences in measured clotting times between both 
analyzers. Only a minority of discrepancies (three out of 194 sam‐
ples) were due to differences in interpretation between both plat‐
forms, all occurring in the mixing assays: For those samples, the NCR 
of the dRVVT mixing step was positive and ICA negative, resulting 
together with a positive dRVVT confirmation in a positive LAC re‐
sult in routine practice, whereas the negative ICA did not result in 
the launch of a confirmation assay with the LAC algorithm. Eleven 
comparable discrepancies in the aPTT mixing test did not end in a 
difference in LAC result since aPTT confirmation tests were negative 
for these samples. Adapting the algorithm by adding the NCR might 
solve this problem, but this would require additional evaluation stud‐
ies. The more that we know that NCR is more sensitive in detecting 
LAC compared to ICA.10,13
Knowledge of an interference due to anticoagulant therapy in a 
given sample may influence the manual interpretation of LAC and 
may lead to a different conclusion than when guidelines would be 
strictly followed. LAC algorithm is in this way less flexible since in‐
terfering medication cannot be taken into account. However, the 
LAC algorithm applies different comments, depending on the results 
of screening, mixing, or confirmation step (Figure 1) and thereby 
warns the operator of possible anticoagulant therapy. This way the 
software aids the laboratory staff in the interpretation of LAC tests 
and in the launching of additional tests (possible testing for factor 
deficiencies or interfering anticoagulant therapy). These comments 
may also be implemented on the laboratory report and thus inform 
that results for LAC may be unreliable in case of the presence of 
anticoagulant medication. However, the final conclusion is always 
revised by the laboratory supervisor who does the clinical valida‐
tion of the result before the result finally leaves the laboratory. An 
algorithm will never take over totally the end conclusion.
Since all reagents, except aPTT confirmation tests, needed to be 
placed onboard before launching the LAC assays on STA R Max, re‐
agent consumption was similar on both analyzers. There was a negli‐
gible reduction of 6% of Staclot® LA confirmation tests. Technician's 
hands‐on time on the analyzer was strongly reduced from 200 to 
80 minutes, making it possible for the technician to perform other 
tasks in the laboratory.
Although the Stago LAC algorithm aids in the standardization 
of LAC interpretation, it is still necessary for each laboratory to 
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calculate their own cutoffs for screening, mixing, and confirmation 
tests or at least verify the cutoffs proposed by the manufacturer. 
In‐house cutoff values have to be applied in the algorithm. When 
necessary due to reagent lot changes, programmed cutoff values can 
be adapted in the LAC algorithm software.
A limiting factor of this study is that the automated LAC algo‐
rithm was compared to the manual method using two different ana‐
lyzers. Since the LAC algorithm is only available on Stago STA R Max 
analyzers, it was not possible to compare both approaches on the 
same analyzer.
Furthermore, the LAC algorithm has been evaluated using Stago 
reagents. Applying different LAC reagents would require additional 
evaluation of the algorithm.
The LAC algorithm was designed following ISTH guidelines. 
Other guidelines (CLSI, British Society for Hematology7,14) exist and 
differ in some ways from the ISTH guidelines.15 Therefore, the LAC 
algorithm would not be applicable in laboratories following other 
guidelines than the ISTH. The rules used in the algorithm cannot be 
adapted and are fixed.
This study evaluated the diagnostic performance of a first ver‐
sion of a LAC algorithm on the current STA Coag Expert software. 
When a software update occurs or LAC algorithm is changed, LAC 
algorithm should be re‐evaluated to ensure its performance.
5  | CONCLUSION
We conclude that the lupus anticoagulant algorithm of the STA Coag 
Expert shows good comparability to the manual interpretation of 
LAC. LAC algorithm may be applied to assist laboratories in auto‐
matic launching of additional tests in interpretation of LAC accord‐
ing to ISTH guidelines and in reducing technician hands‐on time. This 
way, the STA Coag Expert LAC algorithm benefits in the harmoniza‐
tion of LAC interpretation and hence may improve interlaboratory 
comparability of LAC results.
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